Significance of immunohistochemistry in breast cancer

Zaha, Dana Carmen

doi:10.5306/wjco.v5.i3.382

Cited by 193 publications

(130 citation statements)

References 85 publications

(96 reference statements)

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…Immunohistochemical demonstration of Cyclin D1 have become an important mean for assessing cell proliferation, therefore the immunohistological demonstration of cell cycle related antigens such as CDKs which regulated by the different cyclins could provide a good tool for assessment of cellular proliferation [11].…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical Expression of Cyclin D1 in Invasive Ductal Carcinoma of Human Breast

Assem¹,

Youssef²,

Rashad³

et al. 2017

Oncomedicine

View full text Add to dashboard Cite

Cyclin D1 has been observed in many human tumors and is likely to promote cell proliferation and differentiation by shortening the G1/S transition. This work was aimed to evaluate the prognostic role of Cyclin D1 in invasive ductal carcinoma (IDC) and its correlation with other established prognostic parameters of breast cancer. This study was conducted on 40 prospective biopsies taken from patients with breast tumor; 30 cases having IDC and 10 cases with benign tumor as well as 10 normal biopsies. Sections from all cases were subjected to stain with haematoxylin and eosin (H&E) for histopathological examination and immunohistochemical technique for Cyclin D1 in addition using flow cytometric technique to perform cell cycle analysis. Histopathological results showed fibroadenoma and fibrocystic disease in benign cases and IDC with 60% grade II and 40% grade III in malignant cases. Immunohistochemical results revealed higher expression of Cyclin D1 in IDC comparing to normal and benign breast tissues. Statistically there was significant correlation between Cyclin D1 scores and the positivity of estrogen receptor (ER) and progesterone receptor (PR), and no significant correlation was seen between Cyclin D1 and S-phase %. It could be suggested that Cyclin D1 protein may be a valuable prognostic marker in IDC and can be targeted in the future therapeutic approaches.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunohistochemical Expression of Cyclin D1 in Invasive Ductal Carcinoma of Human Breast

Assem¹,

Youssef²,

Rashad³

et al. 2017

Oncomedicine

View full text Add to dashboard Cite

show abstract

“…Individual markers or more often panels of various marker proteins can be used to characterize various tumour subtypes, confirm tissue of origin, distinguish metastatic from primary tumour and provide additional information which may be important for prognosis, predicting response to therapy or evaluating residual tumour post-treatment [7].…”

Section: Case Discussionmentioning

confidence: 99%

An Unusual Case of Ductal Carcinoma in Situ

AK¹

2017

JCPCR

View full text Add to dashboard Cite

Submit Manuscript | http://medcraveonline.com Ductal carcinoma in situ is defined by the proliferation of tumor cells within the terminal lobular unit with preservation of the basement membrane [2]. Before screening mammography, DCIS accounted only the 0.8 to 5% of all breast cancers [2].Currently it represents 25% of all cancers in the US [2]. It was first recognized in the early 20th century, mainly in mammography specimens with invasive malignancy [2]. Studies indicate that it is a precursor of invasive carcinoma in an average time of 5 to 8 years [2].25-50% of women who have untreated DCIS will develop invasive cancer in the same quadrant of the breast. If ductal carcinoma in situ is not completely resected, 33% will recur and 50% of these will be invasive carcinoma [2].The American College of Radiology recommends annual screening mammography for women starting at age 40. Breast cancer incidence increases substantially around age 40 and even earlier for high risk women and women of color [3]. Case Presentation40 years old female with an antecedent of cosmetic surgery with placement of breast implants 10 years ago. Her current condition is recent palpable area on right breast. Mammongraphy and ultrasound were performed on January 8, 2015 (Figure 1-10).Left breast without findings of interest on mammography and ultrasound. The palpable finding of right breast has an indeterminate appearance. Classifying BI-RADS category 4c: finding with high suspicion of malignancy. AbstractDuctal carcinoma in situ (DCIS; intraductal carcinoma) is a noninvasive breast cancer originating from the cells that line the mammary ducts. Patients with DCIS can be asymptomatic at the time of presentation (radiographic findings on mammogram) or present with symptoms such as a palpable mass or nipple discharge [1]. We present an unusual case of DCIS in a 40 year old woman with recent palpable mass. After diagnostic mammography and breast ultrasound, BIRADS 4c category was assigned and biopsy was performed. Pathology report indicates the presence of two histollogical types: DCIS and also invasive lobulillar carcinoma.

show abstract

“…Biological subtypes of breast cancer determined by ER, PR, HER-2, and Ki-67 are the most common prognostic and therapeutic markers [54], and are widely used for disease stratification. These subtypes are relevant to the expression of genes to specify the tumor characteristics [55][56][57][58], and strongly supported by The 12th St Gallen International Breast Cancer Conference (2011) as the definition of therapy indication, as the subtypes incorporate many of the risk and predictive factors of breast cancer [59].…”

Section: Discussionmentioning

confidence: 99%

The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT

Moon

Noh

Kim

et al. 2016

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose This study investigates the correlation of retention index (RI) using the dual phase FDG PET/CT scan with the breast cancer biomarkers. Methods A total of 55 patients with breast cancer underwent dual phase FDG PET/CT scans (60 and 120 min after FDG injection) before treatment. SUVmax and SUVmean of the primary breast tumors were measured, then the percent change of SUVmax and SUVmean between the two scans were calculated, and denoted as RImax and RImean, respectively. After the surgical resection of the breast tumor, the status of biomarkers (ER, PR, and HER-2) was evaluated in the postsurgical specimen.

show abstract

Significance of immunohistochemistry in breast cancer

Cited by 193 publications

References 85 publications

Immunohistochemical Expression of Cyclin D1 in Invasive Ductal Carcinoma of Human Breast

Immunohistochemical Expression of Cyclin D1 in Invasive Ductal Carcinoma of Human Breast

An Unusual Case of Ductal Carcinoma in Situ

The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT

Contact Info

Product

Resources

About